The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY , Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced... Read More

SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025 . Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an... Read More

SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc . , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial results on Thursday November 13, 2025 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis , MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's... Read More

SALT LAKE CITY , Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27 th Annual Global Investment Conference on Friday, September 5, 2025 at 7:00 a.m. ET . Zhenya Lindgardt, President... Read More

SALT LAKE CITY , Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc . , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025 . Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted... Read More

SALT LAKE CITY , July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6, 2025 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc . , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference Date: June 3 – 5, 2025 1X1... Read More

SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025 , from 9:30 – 9:55 a.m. ET . Zhenya Lindgardt, President and CEO, will... Read More

Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY , May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more... Read More

SALT LAKE CITY , May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025 . Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical... Read More

SALT LAKE CITY , April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025... Read More

SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024 . Recent Highlights: On January 6, 2025 , the Society for Maternal Fetal Medicine ("SMFM")... Read More

SALT LAKE CITY , March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45 th Annual Health Care Conference on Wednesday, March 5, 2025 , from 9:50 a.m. – 10:20 a.m. ET . Zhenya Lindgardt, President... Read More

SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company ® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per... Read More

SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics , Inc ., The Pregnancy Company ® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to... Read More

Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY , Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025 , from 5:00... Read More

SALT LAKE CITY , Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco . Zhenya Lindgardt, President and CEO,... Read More

SALT LAKE CITY , Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy... Read More

SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36 th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET . Zhenya Lindgardt, President and CEO, will... Read More

SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET . Zhenya Lindgardt,... Read More

SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024 . Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical... Read More

SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , Sept. 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright Global Investment Conference on Wednesday, September 11, 2024 at 10:00 a.m. ET . Zhenya Lindgardt, President and CEO,... Read More

SALT LAKE CITY , Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference: UBS Genomic Medicine Summit, August 13-14 . President and Chief Executive Officer,... Read More

SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024 . Recent Highlights: Publication of positive AVERT PRETERM TRIAL ( Serum Assessment of Preterm Birth... Read More

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024 , after the close of the market. The Company will host a corresponding... Read More

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics , an... Read More

SALT LAKE CITY , July 1, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024 , the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes... Read More

SALT LAKE CITY , May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased... Read More

SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024 . Recent Highlights: Submitted manuscript of PRIME study interim analysis results for peer-reviewed... Read More

SALT LAKE CITY , April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023 . Recent Highlights: Announced that the Data Safety Monitoring Board (DSMB) overseeing... Read More

SALT LAKE CITY , March 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 44 th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET . Zhenya Lindgardt, President and CEO, will... Read More

SALT LAKE CITY , Dec. 6, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal P rematurity R isk Assessment Combined with Clinical I nterventions for Improved Neonatal Outco ME s... Read More

SALT LAKE CITY , Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35 th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City . Doug Fisher , Sera's... Read More

SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2023 ended September 30, 2023 . Recent Highlights: Sera Board of Directors approved permanent President and CEO and CFO... Read More

SALT LAKE CITY , Oct. 25, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2023 financial results on Wednesday, November 8, 2023 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming Cantor Fitzgerald Global Healthcare Conference 2023 to be held September 26-28, 2023 in New York City . Zhenya Lindgardt,... Read More

SALT LAKE CITY , Aug. 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2023 ended June 30, 2023.... Read More

SALT LAKE CITY , July 31, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023 , after the close of the market. The Company will host a corresponding... Read More

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy House to Evaluate Best Pathways Toward Targeting Enhanced Revenue Generation at Significantly Reduced Operating Costs Nadia Altomare Expected to Move from Chief Commercial Officer to Consulting Role to Support Driving Efficiency and... Read More

SALT LAKE CITY , May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield , M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the... Read More

SALT LAKE CITY , May 10, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2023 ended March 31, 2023 . Recent Highlights: Announced positive top-line results from the AVERT PRETERM TRIAL ( Serum... Read More

SALT LAKE CITY , April 27, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2023 financial results on Wednesday, May 10, 2023 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2022 ended December 31, 2022 . Recent Highlights: Announced positive top-line results from the AVERT PRETERM TRIAL... Read More

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2022 financial results on Wednesday, March 22, 2023 , after the close of the market. The Company will host a corresponding... Read More

SALT LAKE CITY , Feb. 23, 2023 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company ® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming Cowen Health Care Conference March 6-8, 2023 in Boston and the Oppenheimer 33rd Annual Healthcare Conference held to be held... Read More

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY , Feb. 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced top-line results... Read More

Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce SALT LAKE CITY and ARLINGTON, Va. , Nov. 29, 2022 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Fors Marsh , a... Read More